Lyxumia lixisenatide: Additional Phase III data

Additional data from the double-blind, international Phase III GetGoal Duo 1 trial in 446 Type II diabetics inadequately controlled with oral anti-diabetic drugs showed that Lyxumia as an add-on to Lantus insulin glargine and metformin significantly reduced HbA1c from 8.6% at baseline to 6.96% at week 24, the primary endpoint, vs. 7.3% for placebo plus Lantus and metformin (p<0.0001). Patients received placebo or once-daily Lyxumia as an add-on to Lantus and metformin for 24 weeks following a 12-week run-in period with Lantus. Data were presented at the American Diabetes Association meeting in Philadelphia. Sanofi previously reported that Lyxumia met the primary endpoint in the trial (see BioCentury, Dec. 12, 2011). ...